Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel With or Without Bevacizumab in HER2-Negative Metastatic Breast Cancer
NCT00217672Phase 2Completed
- Sponsor
- TRIO
- Start
- May 2005
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by TRIO. Started May 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00217672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217672.